Sanofi India Share Price

Kindly refer the attachment

• BSE India
• 20 hours 31 minutes ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Sanofi India announced Q2CY26 results</strong></span></h3> <p _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> The company reported a total income of Rs 4,439 million in Q2CY26, representing a YoY increase of 6.96% compared to Rs 4,150 million in Q2CY25. On a QoQ basis, total income declined by 6.88% from Rs 4,767 million in Q1CY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> Revenue for Q2CY26 stood at Rs 4,377 million, marking a YoY growth of 7.73% against Rs 4,063 million in Q2CY25. It saw a QoQ decrease of 7.33% from Rs 4,723 million in Q1CY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> PBT for the quarter reached Rs 1,123 million, showing a robust YoY increase of 19.34% from Rs 941 million in Q2CY25. However, it recorded a QoQ decline of 18.56% from Rs 1,379 million in Q1CY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit (PAT):</strong> The company earned a net profit of Rs 835 million in Q2CY26, up 20.14% YoY from Rs 695 million in Q2CY25. On a QoQ basis, PAT decreased by 18.61% compared to Rs 1,026 million in Q1CY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Other Income:</strong> Other income for the quarter was reported at Rs 62 million, compared to Rs 87 million in Q2CY25 and Rs 44 million in Q1CY26.</li> </ul> <p _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Diabetes Portfolio:</strong> The Insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, supported by brands such as Lantus, Toujeo, and Apidra.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Market Share:</strong> Sanofi maintained a leadership position in the basal analog market with a 58% value market share and a 61% volume market share.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Segment Performance:</strong> The company operates under a single business segment, which is the ‘Pharmaceutical Business’.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Public Sector Expansion:</strong> The public sector business saw a significant acceleration of 70%, driven by the opening of new accounts for Toujeo and Soliqua under the CARE Accounts initiative.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Strategic Partnerships:</strong> Partnership revenues in Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments grew by 2% in Q2CY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Sales Mix:</strong> Domestic net sales grew by 8% YoY, while total net sales grew by 6% YoY. Export sales remained broadly stable despite global headwinds.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Efficiency:</strong> Profit before tax as a percentage of net sales improved to 27% in Q2CY26, up from 24% in Q2CY25, supported by disciplined cost management.</li> </ul> <p><strong>Deepak Arora, Managing Director, said:</strong> "Q2CY26 marks another chapter of purposeful, profitable growth for Sanofi India, with our diabetes portfolio posting double-digit growth for the second consecutive quarter and profit before tax growing 19%. These results reflect the discipline and momentum we have built across the business.</p> <p>Our acceleration in the public sector demonstrates that we are not just growing; we are broadening access to innovative therapies across the country. With a 57.3% value share in the diabetes injectable segment, a modernized go-to-market model, and a business that has grown 17% in the first half of 2026, the foundation for sustainable, long-term value creation is firmly in place.</p> <p>As we mark seven decades of serving Indian patients, guided by our purpose to chase the miracles of science, we remain focused on capturing the immense growth opportunity that India's diabetes landscape presents."</p> <p><a class="lb" href="/get-document/post/pdf/5765158/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 day 18 hours ago

Kindly refer the attachment

• BSE India
• 1 day 18 hours ago